Antibody Coupled T-Receptor Therapy Market Size is predicted to witness a 5.89% CAGR during the forecast period for 2023-2031.
ACR therapy is an immunotherapy modality to have the patient's T cells fight cancer. Immune function is supported by T cells. The capacity of the immune system to detect and eradicate damaged or sick cells relies on these highly specialized white blood cells. Antigens are unique identifiers on cell surfaces that T cells can detect. When the immune system identifies a cell that expresses an antigen that suggests danger, like a cancer cell, it goes into overdrive.
The ACTR approach combines the best features of antibody and T-cell treatments. One approach is the expression of a receptor that can identify a specific antigen in cancer cells by genetically altering T cells. These T cells undergo additional modifications, one of which is the development of an antibody-binding receptor. Furthermore, ACTR treatment has shown promising results. An important component of the immune system, the lymphatic system, is the site of lymphoma formation. This treatment efficiently eliminates lymphoma cells by utilizing the patient's T cells modified with ACTR receptors.
However, the market growth is hampered by the strict regulatory criteria for the safety and health of antibody-coupled T-receptor therapy and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity antibody-coupled T-receptor therapy; a larger patient population may not be able to afford the development and administration of ACTR therapy due to the high costs involved. Particularly in areas with limited healthcare resources, the high costs may discourage its use due to the complicated production processes, extensive clinical testing, and specialist equipment required.
In addition, well-established immunotherapies such as CAR-T cell therapy are a threat to ACTR therapy because of their popularity in clinical practice. As consumers and healthcare professionals consider the pros and cons of various treatment options, the extensive availability and success of these alternatives could slow down the rise of the ACTR therapy market. This reflects the great efforts of all those involved in reacting to the global public health crisis precipitated by COVID-19 and the decades of prior advancement in allowing technology to generate antibody treatments. Another antibody that has just received approval for COVID-19 and has already received approval in other situations is tocilizumab, an anti-IL-6R antibody.
The antibody-coupled t-receptor therapy market is segmented based on the indication. By indication, the market is segmented into lymphoma, breast cancer, neuroblastoma, and other indications.
The lymphoma antibody coupled t-receptor therapy market is expected to lead with a major global market share in 2022. Lymphoma is the cancer that develops in the immune system's lymphocytes, which fight infections. These cells have several potential locations, including lymph nodes, the spleen, the thymus, and bone marrow. The hallmark of lymphoma is the aberrant and uncontrolled growth of lymphocytes.
The neuroblastoma industry comprises the bulk of antibody-coupled t-receptor therapy because immature nerve cells can give rise to neuroblastoma, a malignant tumour in several body parts. Situated on the kidneys' upper surfaces and similar in origin to nerve cells, kidneys are the most frequent sites for developing neuroblastoma, especially in countries like the US, Germany, the UK, China, and India.
The North American antibody-coupled t-receptor therapy market is expected to record the maximum market share in revenue in the near future. It can be attributed to the highly developed healthcare infrastructure, favourable reimbursement policies, partnerships, new product launches, and prominent pharmaceutical and biotechnology companies engaged in immunotherapy; the region is anticipated to experience accelerated growth in the antibody-coupled t-receptor therapy market during the forecast period. In addition, Asia Pacific is estimated to grow rapidly in the global Antibody Coupled T-receptor Therapy Market due to the huge amount of registered clinical trials linked to the treatments. The significant focus on government funding and reforms is another factor expected to contribute to expanding the region's chimeric antigen receptor (CAR)-T cell therapy market in the coming years.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 5.89% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Unum Therapeutics, Pfizer Inc., Novartis AG, Johnson and Johnson Services, Inc., GSK plc, and The Bristol-Myers Squibb Company. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Anti-body Coupled T Receptor Therapy Market Snapshot
Chapter 4. Global Anti-body Coupled T Receptor Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Indication Estimates & Trend Analysis
5.1. By Indication, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Indication:
5.2.1. Lymphoma
5.2.2. Breast Cancer
5.2.3. Neuroblastoma
5.2.4. Other Indications
Chapter 6. Anti-body Coupled T Receptor Therapy Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031
6.1.2. North America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
6.2. Europe
6.2.1. Europe Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, 2019-2031
6.2.2. Europe Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
6.3. Asia Pacific
6.3.1. Asia Pacific Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, 2019-2031
6.3.2. Asia Pacific Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
6.4. Latin America
6.4.1. Latin America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
6.4.2. Latin America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
6.5.2. Middle East & Africa Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Unum Therapeutics
7.2.2. Pfizer Inc.
7.2.3. Novartis AG
7.2.4. Johnson and Johnson Services, Inc.
7.2.5. GSK plc
7.2.6. The Bristol-Myers Squibb Company
Antibody-Coupled T-Receptor Therapy Market By Indication-
Antibody-Coupled T-Receptor Therapy Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
